Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States

Table 2

Basic description of the AF study cohorts.

Data source	Patients (N)	Mean age (±SD) at first OAC prescription	% female
Belgium LPD	6546	74.5 (10.5)	45
France DA	5053	73.6 (10.5)	43
Germany DA	72,297	74.1 (10.1)	47
UK THIN	52,720	74.1(10.5)	44
UK CPRD	48,830	74.3 (10.5)	44
US LRxDx	3,195,578	70.3 (10.5)	45
US PMTX	193,118	63.1 (11.0)	35
US Marketscan CCAE	97,220	56.2 (7.1)	31
US Marketscan MDCR	170,971	78.0 (7.3)	47

Some patients could potentially contribute to more than one database, for example, THIN and CPRD databases in the UK. AF: atrial fibrillation; CCAE: Commercial Claims and Encounters; CPRD: Clinical Practice Research Datalink; DA: Disease Analyzer; IMRD: IQVIA Medical Research Data UK; LPD: Longitudinal Patient Database; LRxDx: Longitudinal Prescription Diagnosis database; MDCR: Medicare Supplemental and Coordination of Benefits; OAC: oral anticoagulant; PMTX: Pharmetrics; SD: standard deviation.